MARIA FRANCIS, D.O.
Rheumatology Physician · NEW LENOX, IL
Individual Active NPI 1871828780
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 483 | 236,395 | $6,981,853 | $2,728,618 | $2,175,723 |
| 2023 | 437 | 173,110 | $6,820,901 | $2,787,641 | $2,214,881 |
| 2022 | 342 | 112,809 | $5,214,332 | $2,115,290 | $1,683,933 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0878 | Injection, daptomycin, 1 mg | 91,750 | $0 | $0 |
| J0485 | Injection, belatacept, 1 mg | 37,752 | $4 | $3 |
| J0875 | Injection, dalbavancin, 5 mg | 13,700 | $15 | $12 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 13,230 | $18 | $14 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 8,400 | $22 | $17 |
| J2357 | Injection, omalizumab, 5 mg | 7,740 | $38 | $30 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 4,590 | $44 | $35 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4,230 | $31 | $24 |
| J0897 | Injection, denosumab, 1 mg | 2,160 | $25 | $20 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 1,528 | $0 | $0 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 937 | $0 | $0 |
| J0517 | Injection, benralizumab, 1 mg | 840 | $165 | $131 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Rheumatology Physician | 207RR0500X | ✓ | 036118833 | IL |
| Internal Medicine Physician | 207R00000X | 02003400A | IN |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Rheumatology Physician providers in Illinois
- NPI 1801950852
- NPI 1790102804
- NPI 1932546249
- NPI 1083124465
- NPI 1144473745
- NPI 1619921541
- NPI 1386075893
- NPI 1831316983
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.